Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on TechCrunch.